Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Investor's Business Daily on MSN4h
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy PointsNetflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can significantly improve symptoms.
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback